Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, Blennow K, Schott JM, Zetterberg H. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016 Mar 1;86(9):829-35. Epub 2016 Jan 29 PubMed.
AlzBiomarker Database
Meta-Analysis
- AD vs CTRL : neurogranin (CSF)
- CTRL vs AD : neurogranin (CSF)
- DLB vs AD : neurogranin (CSF)
- FTD vs AD : neurogranin (CSF)
- MSA vs AD : neurogranin (CSF)
- PD vs AD : neurogranin (CSF)
- PSP vs AD : neurogranin (CSF)
Curated Study Data
| Biomarker (Source) |
Cohort (N) |
Measurement Mean ± SD |
Method; Assay Name; Manufacturer |
Diagnostic Criteria |
|---|---|---|---|---|
| neurogranin (CSF) |
AD (100) |
612 ± 539 ng/L § |
Electrochemiluminescence; In-house; In-house |
|
| neurogranin (CSF) |
CTRL- CNC (19) |
242 ± 177 ng/L § |
Electrochemiluminescence; In-house; In-house |
|
| neurogranin (CSF) |
DLB (13) |
205 ± 140 ng/L § |
Electrochemiluminescence; In-house; In-house |
McKeith et al., 1996 |
| neurogranin (CSF) |
FTD- Speech variant (21) |
280 ± 146 ng/L § |
Electrochemiluminescence; In-house; In-house |
1994 |
| neurogranin (CSF) |
FTD- bvFTD (20) |
249 ± 201 ng/L § |
Electrochemiluminescence; In-house; In-house |
1994 |
| neurogranin (CSF) |
MSA (29) |
212 ± 128 ng/L § |
Electrochemiluminescence; In-house; In-house |
Gilman et al., 2008 |
| neurogranin (CSF) |
PD (31) |
270 ± 236 ng/L § |
Electrochemiluminescence; In-house; In-house |
Hughes et al., 1992 |
| neurogranin (CSF) |
PSP (46) |
255 ± 211 ng/L § |
Electrochemiluminescence; In-house; In-house |
Litvan et al., 1996 |
§ Data supplied to Alzforum by author
Recommends
Please login to recommend the paper.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.